Cancer clinical trials in the region Provence-Alpes-Côte d'Azur
434 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Lung cancer
#NCT07218146
#2025-522818-23-00
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at localized stage
Chemotherapy
Bispecific T-cell engager antibodies
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Chemotherapy
Bispecific T-cell engager antibodies
12 recruiting sites
Zai Lab (Shanghai) Co., Ltd
Phase 3
Lung cancer
#NCT07365241
#2025-523819-11-00
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Bispecific T-cell engager antibodies
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Antibody Drug Conjugates (ADC)
1 recruiting site
Abbvie
Phase 3
Lung cancer
#NCT06170788
#2023-503376-24-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Metastatic
Required PDL1 statuses
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
Merck Sharp & Dohme LLC
Phase 3
Lung cancer
#NCT06350097
#2023-509883-89-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
EGFR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
AstraZeneca
Phase 3
Amyloidosis
#NCT07207811
#2024-518899-31-00
Required histologic types
Other
Required organ involvement status
Presence
Required organ involvements
Cardiac
19 recruiting sites
Novo Nordisk A/S
Phase 3
Lymphoma
#NCT06149286
#2022-503092-28-00
Required histologic types
B cell lymphoma
Required histologic sub types
Follicular lymphoma
Marginal zone lymphoma
Required central nervous system lesions
None
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
Chemotherapy
Monoclonal antibodies
Excluded previous treatments
Systemic Treatment-Naive
16 recruiting sites
Regeneron Pharmaceuticals
Phase 3
Endometrial cancer
#NCT06989112
#2023-508056-19-00
Required histologic sub types
Endometrioid adenocarcinoma
Serous adenocarcinoma
Clear cell carcinoma
Dedifferentiated and undifferentiated endometrial ...
Carcinosarcoma
Required FIGO stages
Stage III
Stage IV
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
HER2
MSS/pMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Radiotherapy
Hormone therapy
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Radiotherapy
Hormone therapy
Excluded previous treatments at localized stage
Immunotherapy
Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Antibody Drug Conjugates (ADC)
10 recruiting sites
Phase 3
Breast cancer
#NCT05232916
#2023-504323-25-01
Required HER2 statuses
HER2 Positive
Required disease stage
Localized
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Targeted therapy
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
22 recruiting sites
Greenwich LifeSciences, Inc.
Phase 3
Lung cancer
#NCT06203210
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
13 recruiting sites
Daiichi Sankyo
Phase 3
Breast cancer
#NCT06982521
#2025-523083-21-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
PIK3CA
Required number of previous lines of therapy for current stage of disease
None
1
2
Required previous treatments at localized stage
Targeted therapy
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Targeted therapy
Hormone therapy
Excluded genetic anomalies
AKT
PTEN
Excluded previous treatments at localized stage
Immunotherapy
Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Antibody Drug Conjugates (ADC)
17 recruiting sites
Relay Therapeutics, Inc.